What is AARD's net gains (losses) on investments?

AARD (AARD) reported net gains (losses) on investments of -$13K in Q1 2026.

How has AARD's net gains (losses) on investments changed year-over-year?

AARD's net gains (losses) on investments increased by 13.3% year-over-year, from -$15K to -$13K.

Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.

Relmada Therapeutics, Inc.RLMD

-$540.1K-447%

Revenue-—

Operating income-$22.5M-115%

Net income-$21.6M-132%

EPS (diluted)-$0.99-39.4%

Cash & equivalents$62.4M+136%

Total debt$336.0K-53.7%

Total equity$87.0M-42.3%

Total assets$98.6M-37.2%

Operating cash flow-$18.9M-65.7%

CapEx--100%

Free cash flow-$16.8M-117%

Market cap$124.35M-58.6%

Enterprise value$62.25M-77.4%

Return on equity-58.8%—

Debt / equity0×0.0×

Current ratio8.1×-17.8×

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is AARD's net gains (losses) on investments?: AARD (AARD) reported net gains (losses) on investments of -$13K in Q1 2026.
How has AARD's net gains (losses) on investments changed year-over-year?: AARD's net gains (losses) on investments increased by 13.3% year-over-year, from -$15K to -$13K.
What does net gains (losses) on investments mean?: Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.